Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
Background: Combination therapy with immune checkpoint inhibitors (ICIs) has been widely used for clinical treatment in recent years, which has a better survival benefit. However, not all patients can derive clinical benefit from combination immunotherapy. Therefore, it is necessary to explore the b...
Guardado en:
Autores principales: | Yuqian Feng (Autor), Huimin Jin (Autor), Kaibo Guo (Autor), Yuying Xiang (Autor), Yiting Zhang (Autor), Wurong Du (Autor), Minhe Shen (Autor), Shanming Ruan (Autor) |
---|---|
Formato: | Libro |
Publicado: |
Frontiers Media S.A.,
2021-02-01T00:00:00Z.
|
Materias: | |
Acceso en línea: | Connect to this object online. |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pratibha Pandey, et al.
Publicado: (2022) -
PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Yuncong Liu, et al.
Publicado: (2019) -
Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Yiting Wang, et al.
Publicado: (2020) -
A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors
por: Yongming Chen, et al.
Publicado: (2024) -
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Jinhua Liu, et al.
Publicado: (2021)